27 results on '"Pagliai, F."'
Search Results
2. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis
- Author
-
Saccardi, R, Tyndall, A, Coghlan, G, Denton, C, Edan, G, Emdin, M, Farge, D, Fassas, A, Finke, J, Furst, D, Lassus, M, Mancardi, G, Miniati, I, Mini, E, Pagliai, F, Passweg, J, Pignone, A, van Laar, J M, Bocelli-Tyndall, C, and Matucci-Cerinic, M
- Published
- 2004
- Full Text
- View/download PDF
3. Autologous HSCT for severe progressive multiple sclerosis in the Italian prospective, multicentre GITMO-Neuro trial: long-term follow-up
- Author
-
Saccardi, R., Mancardi, G., Bosi, A., Bruzzi, P., Di Bartolomeo, P., Donelli, A., Filippi, M., Guerrasio, A., Gualandi, F., La Nasa, G., Capello, E., Papineschi, F., Donnini, I., Pagliai, F., Di Gioia, M., and Marmont, A.
- Published
- 2008
4. The cord blood programme of the Florence Cord Blood Bank
- Author
-
Lombardini, L., Saccardi, R., Urbani, S., Caporale, R., Pizzano, P., Carraresi, A., Bufano, P., Pagliai, F., and Bosi, A.
- Published
- 2004
5. Post-thawing PBPCs washing protocol using the SEPAX System
- Author
-
Saccardi, R., Bufano, P., Caporale, R., Carraresi, A., Lombardini, L., Pagliai, F., Pizzano, P., Urbani, S., Bosi, A., Azzalin, S., Mizeret, J., Tichelli, A., Meyer, S., Landi, L., and Elssner, C.
- Published
- 2004
6. Immunoablation followed by stem cell rescue in refractory multiple sclerosis: long-term follow-up of MRI and quality of life
- Author
-
Saccardi, R., Mancardi, G. L., Di Bartolomeo, P., Donelli, A., Filippi, M., Gualandi, F., La Nasa, G., Murialdo, A., Pagliai, F., Papineschi, F., Saglio, G., Solari, A., and Marmont, A.
- Published
- 2004
7. SARS-CoV-2 was already circulating in Italy, in early December 2019.
- Author
-
GRAGNANI, L., MONTI, M., SANTINI, S. A., MARRI, S., MADIA, F., LORINI, S., PETRACCIA, L., STASI, C., BASILE, U., LUTI, V., PAGLIAI, F., SACCARDI, R., and ZIGNEGO, A. L.
- Abstract
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified in China, in December 2019 determines COronaVIrus Disease 19 (COVID-19). Whether or not the virus was present in Italy earlier the first autochthonous COVID-19 case was diagnosed is still uncertain. We aimed to identify anti-SARS-CoV-2 antibodies in sera collected from 4th November 2019 to 9th March 2020, in order to assess the possible spread of the virus in Italy earlier than the first official national diagnosis. PATIENTS AND METHODS: Anti-SARS-CoV-2 antibodies were evaluated in retrospective serum samples from 234 patients with liver diseases (Hep-patients) and from 56 blood donors (BDs). We used two rapid serologic tests which were confirmed by a validated chemoluminescence assay. RESULTS: Via rapid tests, we found 10/234 (4.3%) IgG-positive and 1/234 (0.4%) IgM-positive cases in the Hep-patient group. Two/56 (3.6%) IgG-positive and 2/56 (3.6%) IgM-positive cases were detected in BD group. Chemoluminescence confirmed IgG-positivity in 3 Hep-patients and 1 BD and IgM-positivity in 1 Hep-patient. RNAemia was not detected in any of the subjects, rendering the risk of transfusion transmission negligible. CONCLUSIONS: O ur r esults s uggest a n e arly circulation of SARS-CoV-2 in Italy, before the first COVID-19 cases were described in China. Rapid tests have multiple benefits; however, a confirmation assay is required to avoid false positive results. [ABSTRACT FROM AUTHOR]
- Published
- 2021
8. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis
- Author
-
Capello E, Saccardi R, Murialdo A, Gualandi F, Pagliai F, Bacigalupo A, Marmont A, Uccelli A, Inglese M, Bruzzi P, Sormani MP, Cocco E, Meucci G, Massacesi L, Bertolotto A, Lugaresi A, Merelli E, Solari A, Filippi M, Mancardi GL, Italian GITMO-Neuro Intergroup on ASCT for Multiple Sclerosis, La Nasa G, Marrosu MG, Derchi V, Di Bartolomeo P, Farina D, Iarlori C, Tartaro A, Repice A, Pellicanò G, Dogliotti L, Parodi RC, Schenone A, Donelli A, Casoni F, Cavalleri F, Capobianco M, Guerrasio A, Duca S, Papineschi F, Scappini B, Mosti S, Abbruzzese A, Capello, E, Saccardi, R, Murialdo, A, Gualandi, F, Pagliai, F, Bacigalupo, A, Marmont, A, Uccelli, A, Inglese, M, Bruzzi, P, Sormani, Mp, Cocco, E, Meucci, G, Massacesi, L, Bertolotto, A, Lugaresi, A, Merelli, E, Solari, A, Filippi, M, Mancardi, Gl, Italian GITMO-Neuro Intergroup on ASCT for Multiple, Sclerosi, La Nasa, G, Marrosu, Mg, Derchi, V, Di Bartolomeo, P, Farina, D, Iarlori, C, Tartaro, A, Repice, A, Pellicanò, G, Dogliotti, L, Parodi, Rc, Schenone, A, Donelli, A, Casoni, F, Cavalleri, F, Capobianco, M, Guerrasio, A, Duca, S, Papineschi, F, Scappini, B, Mosti, S, and Abbruzzese, A
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,medicine.medical_treatment ,Inflammation ,Dermatology ,Transplantation, Autologous ,Severity of Illness Index ,methods ,Autologous stem-cell transplantation ,Internal medicine ,medicine ,Humans ,Severe disability ,Salvage Therapy ,Transplantation ,Adult, Hematopoietic Stem Cell Transplantation ,methods, Humans, Immunosuppressive Agents ,therapeutic use, Italy, Magnetic Resonance Imaging, Multiple Sclerosis ,diagnosis/immunology/therapy, Salvage Therapy, Severity of Illness Index, Transplantation ,Autologous, Treatment Outcome ,business.industry ,Multiple sclerosis ,Hematopoietic Stem Cell Transplantation ,diagnosis/immunology/therapy ,Immunosuppression ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Psychiatry and Mental health ,Haematopoiesis ,Treatment Outcome ,Italy ,therapeutic use ,Neurology (clinical) ,medicine.symptom ,Stem cell ,business ,Autologous ,Immunosuppressive Agents - Abstract
Aggressive forms of multiple sclerosis (MS) represent a limited group of demyelinating diseases that rapidly progress to severe disability. Currently available therapies are poorly effective against these clinical entities. Recently, it has been demonstrated that intense immunosuppression followed by autologous haematopoietic stem cell transplantation (AHSCT) can affect the clinical course of individuals with severe MS and completely abrogate the inflammatory activity detected by MRI. We report the result of the Italian phase 2 GITMO study, a multicentre study in which 21 MS patients, who were rapidly deteriorating and not responding to the usual therapeutic strategies, were treated with this procedure. The clinical effect of the treatment is long lasting, with a striking abrogation of inflammation detected by MRI findings. These results support a role for intense immunosuppression followed by ASCT as treatment in rapidly evolving MS cases unresponsive to conventional therapies.
- Published
- 2005
9. AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANTATION IN SEVERE PROGRESSIVE MULTIPLE SCLEROSIS
- Author
-
Saccardi, R., Mancardi, G.L., Bacigalupo, A., Di Bartolomeo, P., Gualandi, F., La Nasa, G., Murialdo, A., Pagliai, F., Papineschi, F., and Marmont, A.M.
- Subjects
Multiple sclerosis -- Care and treatment ,Hematopoietic stem cells -- Transplantation ,Health ,Care and treatment - Abstract
Patients and methods: We designed a study mainly directed towards investigating MRI and laboratory changes after autologous PBPC transplantation in patients affected by advanced, poor prognosis and refractory MS. The [...]
- Published
- 2001
10. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study
- Author
-
Roccatagliata, L, Rocca, M, Valsasina, P, Bonzano, L, Sormani, M., Saccardi, R, Mancardi, G, Filippi, M, Marrosu, Mg, La Nasa, G, Cocco, E, Cherchi, V, Lugaresi, A, Di Bartolomeo, P, Farina, D, Ialori, C, Tartaro, A, Massacesi, L, Pagliai, F, Bosi, A, Repice, A, Konze, A, Sardanelli, F, Capello, E, Murialdo, A, Gualandi, F, Parodi, Rc, Dogliotti, L, Marmont, A, Inglese, M, Comi, G, Donelli, A, Merelli, E, Casoni, F, Cavalleri, F, Bertolotto, A, Guerrasio, A, Capobianco, M, Duca, S, Meucci, G, Papineschi, F, Mosti, S, and Abruzzese, A
- Published
- 2007
11. Autologous hematopoietic stem cell transplantation suppresses gadolinium-enhanced MRI activity in multiple sclerosis
- Author
-
Mancardi, GIOVANNI LUIGI, Saccardi, R, Filippi, M, Gualandi, F, Murialdo, A, Inglese, MARIA MATILDE, Marrosu, Mg, Meucci, G, Massacesi, L, Lugaresi, F, Pagliai, F, Sormani, MARIA PIA, Sardanelli, F, Marmont, A, and ITALIAN GITMO NEURO INTERGROUP ON AHSCTMS
- Published
- 2001
12. Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.
- Author
-
Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E., Carreras, E., Saiz, A., Löwenberg, B., te Boekhorst, P. A. W., Gualandi, F., Openshaw, H., Longo, G., Pagliai, F., Massacesi, L., Deconink, E., Ouyang, J., Nagore, F..J. Z., Besalduch, J., and Lisukov, I. A.
- Subjects
HEMATOPOIETIC stem cell transplantation ,AUTOTRANSPLANTATION ,AUTOIMMUNE disease treatment ,MULTIPLE sclerosis ,IMMUNOSUPPRESSION ,NEUROLOGIC examination ,PATIENTS - Abstract
Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995–2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
13. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
- Author
-
Mancardi, G L, Saccardi, R, Filippi, M, Gualandi, F, Murialdo, A, Inglese, M, Marrosu, M G, Meucci, G, Massacesi, L, Lugaresi, A, Pagliai, F, Sormani, M P, Sardanelli, F, Marmont, A, and Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
- Published
- 2001
- Full Text
- View/download PDF
14. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases.
- Author
-
Portaccio, E., Amato, M. P., Siracusa, G., Pagliai, F., Sorbi, S., Guidi, S., Bosi, A., and Saccardi, R.
- Subjects
HEMATOPOIETIC stem cells ,STEM cell transplantation ,INFLAMMATION ,DISEASE relapse ,MULTIPLE sclerosis ,DEMYELINATION ,MYELIN sheath diseases ,VIRUS diseases - Abstract
Autologous hematopoietic stem cell transplantation (AHSCT) has been proposed as a rescue treatment in multiple sclerosis (MS) patients not responding to first- or second-line therapies. To date, most of the treated cases had a secondary progressive disease course. However, patients with high inflammatory activity, but no secondary progression of the disease, could be candidates to take greater advantage of AHSCT. In this paper, we report two cases with very active, relapsing-remitting (RR) MS, who underwent AHSCT, and obtained a dramatic resolution to disease activity. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
15. Rescue treatment with terlipressin in different scenarios of refractory hypotension in newborns and infants.
- Author
-
Filippi L, Gozzini E, Daniotti M, Pagliai F, Catarzi S, and Fiorini P
- Subjects
- Catecholamines therapeutic use, Female, Humans, Hypotension diagnostic imaging, Infant, Infant, Newborn, Intensive Care Units, Neonatal, Italy, Lypressin administration & dosage, Lypressin therapeutic use, Male, Medical Audit, Retrospective Studies, Shock, Septic, Terlipressin, Ultrasonography, Vasoconstrictor Agents administration & dosage, Hypotension drug therapy, Lypressin analogs & derivatives, Vasoconstrictor Agents therapeutic use
- Abstract
Objective: Terlipressin has been successfully used as rescue treatment in hypotensive adults and children with septic shock, but only exceptionally in neonates. The aim of this study is to describe original clinical scenarios in which terlipressin, in newborns and infants, resolved the catecholamine-refractory hypotension., Design: Retrospective study., Setting: Neonatal intensive care unit., Patients: All newborns with hypotension unresponsive to volume replacement and catecholamines, and treated with terlipressin, from January 2008 to December 2009. In this study, also an infant (11 months old) born extremely preterm was included., Interventions: None., Measurements and Main Results: Four hypotensive patients received as rescue therapy terlipressin, which produced a dramatic increase in mean arterial pressure, diuresis, and reduction of lactate levels. In three newborns, hypotension, associated with pulmonary hypertension, was resolved with terlipressin. Two of them (one with systemic inflammatory response syndrome, the other with congenital diaphragmatic hernia) died in the following days for causes unrelated to hypotension; the third (on mild hypothermia for hypoxic-ischemic encephalopathy) recovered. We report furthermore an infant with septic shock and on treatment with β-blockers in whom terlipressin normalized blood pressure. In two patients, cranial Doppler ultrasonography showed the recovery of diastolic cerebral flow in the anterior cerebral artery and the normalization of resistance index within 30 mins from the first dose of terlipressin. In two infants, hyponatremia was detected., Conclusion: Although the number of reported infants is little, terlipressin appears to be an effective rescue treatment in different scenarios of refractory neonatal hypotension. Further controlled studies are required to confirm its efficacy and safety.
- Published
- 2011
- Full Text
- View/download PDF
16. Triazole-modified histone deacetylase inhibitors as a rapid route to drug discovery.
- Author
-
Pirali T, Pagliai F, Mercurio C, Boggio R, Canonico PL, Sorba G, Tron GC, and Genazzani AA
- Subjects
- Cell Line, Tumor drug effects, Enzyme Inhibitors chemical synthesis, Humans, Models, Chemical, Enzyme Inhibitors pharmacology, Histone Deacetylase Inhibitors, Triazoles chemistry
- Published
- 2008
- Full Text
- View/download PDF
17. The chemolithoautotroph Acidithiobacillus ferrooxidans can survive under phosphate-limiting conditions by expressing a C-P lyase operon that allows it to grow on phosphonates.
- Author
-
Vera M, Pagliai F, Guiliani N, and Jerez CA
- Subjects
- Acidithiobacillus growth & development, Acidithiobacillus metabolism, Gene Expression Regulation, Bacterial, Genes, Bacterial, Lyases metabolism, Microbial Viability genetics, Models, Genetic, Oligonucleotide Array Sequence Analysis, Regulon genetics, Reverse Transcriptase Polymerase Chain Reaction, Acidithiobacillus genetics, Lyases genetics, Operon, Organophosphonates metabolism, Phosphates metabolism
- Abstract
The chemolithoautotrophic bacterium Acidithiobacillus ferrooxidans is of great importance in biomining operations. During the bioleaching of ores, microorganisms are subjected to a variety of environmental stresses and to the limitations of some nutrients, such as inorganic phosphate (P(i)), which is an essential component for all living cells. Although the primary source of phosphorus for microorganisms is P(i), some bacteria are also able to metabolize P(i) esters (with a C-O-P bond) and phosphonates (with a very inert C-P bond). By using bioinformatic analysis of genomic sequences of the type strain of A. ferrooxidans (ATCC 23270), we found that as part of a Pho regulon, this bacterium has a complete gene cluster encoding C-P lyase, which is the main bacterial enzyme involved in phosphonate (Pn) degradation in other microorganisms. A. ferrooxidans was able to grow in the presence of methyl-Pn or ethyl-Pn as an alternative phosphorus source. Under these growth conditions, a great reduction in inorganic polyphosphate (polyP) levels was seen compared with the level for cells grown in the presence of P(i). By means of reverse transcription-PCR (RT-PCR), DNA macroarrays, and real-time RT-PCR experiments, it was found that A. ferrooxidans phn genes were cotranscribed and their expression was induced when the microorganism was grown in methyl-Pn as the only phosphorus source. This is the first report of phosphonate utilization in a chemolithoautotrophic microorganism. The existence of a functional C-P lyase system is a clear advantage for the survival under P(i) limitation, a condition that may greatly affect the bioleaching of ores.
- Published
- 2008
- Full Text
- View/download PDF
18. Peripheral blood progenitor uncontrolled-rate freezing: a single pediatric center experience.
- Author
-
Iannalfi A, Bambi F, Tintori V, Lacitignola L, Bernini G, Mariani MP, Sanvito MC, Pagliai F, Brandigi F, Muscarella E, Tapinassi F, and Faulkner L
- Subjects
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Reproducibility of Results, Treatment Outcome, Blood Preservation methods, Cryopreservation methods, Peripheral Blood Stem Cell Transplantation methods
- Abstract
Background: Controlled-rate freezing (CRF) followed by storage in liquid nitrogen is employed by most centers as the standard procedure for peripheral blood progenitor cell (PBPC) cryopreservation. Uncontrolled-rate freezing (URF) at -80 degrees C is more simple, time-saving, less expensive, and, possibly, as effective as CRF. The aim of this retrospective analysis was to compare CRF and URF in childhood transplantation., Study Design and Methods: A total of 54 PBPC transplants performed in 39 children aged 3 to 16 years (median, 9.5 years) were analyzed: 23 transplants in 16 children with CRF versus 31 transplants performed in 23 children with -80 degrees C URF. All grafts contained at least 2 x 10(6) per kg unselected CD34+ cells, enumerated before freezing. Nucleated cells infused ranged from 1.32 x 10(8) to 4.3 x 10(8) per mL with a median of 3.1 x 10(8) per mL. Cryoprotectant solution consisted of a final dimethyl sulfoxide (DMSO) concentration of 10 percent DMSO with autologous plasma., Results: The two study groups did not differ in terms of timing of neutrophil and platelet recovery or transfusion requirements. Adverse events related to graft infusion, severe complications, and transplant-related mortality were not significantly different between CRF and URF groups. In both groups only mild adverse events were observed during graft administration. URF procedures, however, were simpler and less expensive. At a median follow-up of 72 months, no secondary myelodysplasia was observed in either group., Conclusion: Our analysis suggests that URF is safe and effective in the pediatric population.
- Published
- 2007
- Full Text
- View/download PDF
19. Replacement of the lactone moiety on podophyllotoxin and steganacin analogues with a 1,5-disubstituted 1,2,3-triazole via ruthenium-catalyzed click chemistry.
- Author
-
Imperio D, Pirali T, Galli U, Pagliai F, Cafici L, Canonico PL, Sorba G, Genazzani AA, and Tron GC
- Subjects
- 4-Butyrolactone chemistry, Antineoplastic Agents chemical synthesis, Catalysis, Cell Line, Tumor, Humans, Lignans chemical synthesis, Molecular Conformation, Ruthenium chemistry, Triazoles chemistry, Tubulin drug effects, 4-Butyrolactone analogs & derivatives, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Lactones chemistry, Lignans chemistry, Lignans pharmacology, Podophyllotoxin analogs & derivatives
- Abstract
Steganacin and podophyllotoxin are two naturally occurring lignans first isolated from plant sources, which share the capability to disrupt tubulin assembly. Although not strictly essential for its activity, the lactone ring on both structures represents Achilles' heel, as it is a potential site of metabolic degradation and epimerization on its C2 carbon brings about a significant loss in potency. In the present manuscript, we have used the ruthenium-catalyzed [3+2] azide-alkyne cycloaddition, a click-chemistry reaction, to replace the lactone ring with a 1,5-disubstituted triazole in few synthetic steps. The compounds were cytotoxic, although to a lesser degree compared to podophyllotoxin, while retaining antitubulin activity. The present structures might therefore represent a good platform for the fast generation of metabolically stable compounds with few stereogenic centers that might be of value from a medicinal chemistry point of view.
- Published
- 2007
- Full Text
- View/download PDF
20. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents.
- Author
-
Pirali T, Busacca S, Beltrami L, Imovilli D, Pagliai F, Miglio G, Massarotti A, Verotta L, Tron GC, Sorba G, and Genazzani AA
- Subjects
- Anisoles chemistry, Antineoplastic Agents chemistry, Bibenzyls chemistry, Cell Death drug effects, Cell Line, Tumor, Drug Screening Assays, Antitumor, Humans, Molecular Structure, Stilbenes chemistry, Structure-Activity Relationship, Tubulin drug effects, Anisoles chemical synthesis, Anisoles pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents pharmacology, Bibenzyls chemical synthesis, Bibenzyls pharmacology, Furans chemistry, Neuroblastoma drug therapy, Stilbenes chemical synthesis, Stilbenes pharmacology
- Abstract
We have synthesized rigid analogues of combretastatin bearing a furan ring in place of the olefinic bridge. These compounds are cytotoxic at nanomolar concentrations in neuroblastoma cells, display a similar structure-activity relationship compared to combretastatin A4, and inhibit tubulin polymerization. We also show that the furan ring can be further functionalized. Thus, it is possible that combretafurans could act as scaffolds for the development of dual-action antitumoral agents.
- Published
- 2006
- Full Text
- View/download PDF
21. Medicinal chemistry of combretastatin A4: present and future directions.
- Author
-
Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, and Genazzani AA
- Subjects
- Animals, Antineoplastic Agents chemical synthesis, Antineoplastic Agents pharmacology, Antineoplastic Agents, Phytogenic chemical synthesis, Antineoplastic Agents, Phytogenic chemistry, Antineoplastic Agents, Phytogenic pharmacology, Humans, Stilbenes chemical synthesis, Stilbenes pharmacology, Structure-Activity Relationship, Antineoplastic Agents chemistry, Stilbenes chemistry
- Published
- 2006
- Full Text
- View/download PDF
22. Rapid synthesis of triazole-modified resveratrol analogues via click chemistry.
- Author
-
Pagliai F, Pirali T, Del Grosso E, Di Brisco R, Tron GC, Sorba G, and Genazzani AA
- Subjects
- Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Cell Line, Tumor, Drug Screening Assays, Antitumor, Humans, Resveratrol, Stereoisomerism, Stilbenes chemistry, Stilbenes pharmacology, Structure-Activity Relationship, Triazoles chemistry, Triazoles pharmacology, Antineoplastic Agents chemical synthesis, Stilbenes chemical synthesis, Triazoles chemical synthesis
- Abstract
Resveratrol is a phytoalexin able to display an array of biological activities. We decided to replace the double bond with a triazole ring using the archetypical click reaction: the Huisgen [3 + 2] cycloaddition. Seventy-two triazole derivatives were synthesized via a parallel combinatorial approach. Preliminary data suggest that this procedure can lead to the synthesis of compounds that display some, but not all, of resveratrol's actions with increased potency.
- Published
- 2006
- Full Text
- View/download PDF
23. Changes of thyroid function during long-term hGH therapy in GHD children. A possible relationship with catch-up growth?
- Author
-
Seminara S, Stagi S, Candura L, Scrivano M, Lenzi L, Nanni L, Pagliai F, and Chiarelli F
- Subjects
- Body Height drug effects, Child, Female, Follow-Up Studies, Growth Disorders blood, Humans, Male, Matched-Pair Analysis, Recombinant Proteins, Reference Values, Thyroid Gland physiopathology, Thyroid Hormones blood, Growth Disorders drug therapy, Human Growth Hormone deficiency, Human Growth Hormone therapeutic use, Thyroid Gland drug effects
- Abstract
Background: Growth hormone (GH) treatment in patients with GH deficiency (GHD) can determine changes in the thyroid function. The clinical significance of these changes remains controversial, and all studies have so far covered rather a short period--usually no longer than one year., Objective: To determine the effect of long-term recombinant hGH treatment in children with idiopathic GHD on the thyroid function., Patients and Methods: Nineteen prepubertal children (12 boys and 7 girls, mean age 9.2 +/- 3.1 years) with idiopathic GHD were studied and followed for twenty-four months. None of the patients showed multiple pituitary hormone deficiencies. Nineteen healthy children matched for age and sex acted as controls., Results: Patients with GHD showed a significant increase in TT (3) at twelve months and in FT (3) at six and twelve months after starting GH treatment, with a significant decrease at eighteen and twenty-four months. TT (4) level decreased significantly at twelve months and increased significantly at eighteen and twenty-four months. FT (4) also decreased, but only slightly, after twelve months of hGH treatment, and then increased significantly at twenty-four months. TSH levels did not vary significantly during the course of therapy. TT (3)/TT (4) and FT (3)/FT (4) ratios increased significantly after six and twelve months of therapy and significantly decreased later, approaching pre-therapy values. The SDS of Growth Velocity (SDS-GV) increased remarkably during the first year of therapy and then decreased significantly during the second year, although it remained significantly higher than the pre-therapy values. TT (3) and TT (3)/TT (4) ratio displayed a significant correlation with SDS-GV at twelve months of therapy. In a multiple regression analysis with age, bone age, parental height, GH dose, TT (3,) TT (3)/TT (4), and the SDS of IGF-I, only the TT (3)/TT (4) ratio at twelve months of therapy (p < 0.001) was identified as a significant predictor of SDS-GV., Conclusion: Our data confirm that changes in thyroid function are present in GHD children during long-term hGH therapy. These changes probably resulted from the effect of hGH on the peripheral metabolism of thyroid hormones and appear to be transitory, disappearing during the second year of hGH treatment. We speculate on the functional significance of these changes, and in particular, on their role in catch-up growth after hGH therapy.
- Published
- 2005
- Full Text
- View/download PDF
24. Synthesis and biological activity of mustard derivatives of combretastatins.
- Author
-
Coggiola B, Pagliai F, Allegrone G, Genazzani AA, and Tron GC
- Subjects
- Antineoplastic Agents pharmacology, Bibenzyls pharmacology, Humans, Inhibitory Concentration 50, Neuroblastoma metabolism, Neuroblastoma pathology, Nitrogen chemistry, Polymers chemistry, Stilbenes pharmacology, Structure-Activity Relationship, Tubulin chemistry, Tubulin Modulators, Tumor Cells, Cultured, Antineoplastic Agents chemical synthesis, Bibenzyls chemical synthesis, Mustard Plant chemistry, Stilbenes chemical synthesis
- Abstract
A series of chimeric compounds bearing the combretastatin and the nitrogen mustard cores were synthesized. All the compounds were cytotoxic and inhibited tubulin polymerization. When combretastatin was joined to chlorambucil via an ester linkage, the resultant compound proved to be significantly more potent than the two compounds put together. When combretastatin was joined to nitrogen mustard via an ether linkage or when a true hybrid was synthesized, loss of potency was observed. Nonetheless, these latter compounds appeared to be more efficacious and surprisingly were able to inhibit tubulin depolymerization at high concentrations.
- Published
- 2005
- Full Text
- View/download PDF
25. Synthesis and cytotoxic evaluation of combretafurazans.
- Author
-
Tron GC, Pagliai F, Del Grosso E, Genazzani AA, and Sorba G
- Subjects
- Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Benzene Derivatives chemistry, Benzene Derivatives pharmacology, Biopolymers, Cell Line, Tumor, Drug Screening Assays, Antitumor, Fluorescent Antibody Technique, Humans, Molecular Conformation, Oxadiazoles chemistry, Oxadiazoles pharmacology, Structure-Activity Relationship, Tubulin chemistry, Antineoplastic Agents chemical synthesis, Benzene Derivatives chemical synthesis, Oxadiazoles chemical synthesis
- Abstract
Combretastatin A-4 is an antitumoral and antitubulin agent that is active only in its cis configuration. In the present manuscript, we have synthesized cis-locked combretastatins embodying a furazan ring (combretafurazans). To achieve this, we have developed a new strategy that exploits the dehydration of vicinal dioximes using the Mitsunobu reaction. Among the advantages of following such a strategy are the mild conditions used for the construction of the diarylfurazan derivatives, allowing for the presence of highly functionalized substrates and deactivated aromatic rings. Combretafurazans are more potent in vitro cytotoxic compounds compared to combretastatins in neuroblastoma cells, yet maintaining similar structure-activity relationship and pharmacodynamic profiles.
- Published
- 2005
- Full Text
- View/download PDF
26. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life.
- Author
-
Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, Donelli A, Filippi M, Guerrasio A, Gualandi F, La Nasa G, Murialdo A, Pagliai F, Papineschi F, Scappini B, and Marmont AM
- Subjects
- Adult, Antilymphocyte Serum administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carmustine administration & dosage, Cytarabine administration & dosage, Female, Follow-Up Studies, Humans, Male, Melphalan administration & dosage, Middle Aged, Multiple Sclerosis complications, Multiple Sclerosis diagnostic imaging, Podophyllotoxin administration & dosage, Quality of Life, Radiography, Retrospective Studies, Transplantation, Autologous, Treatment Outcome, Hematopoietic Stem Cell Mobilization, Multiple Sclerosis therapy, Peripheral Blood Stem Cell Transplantation adverse effects, Transplantation Conditioning
- Abstract
Hematopoietic stem cell transplantation (HSCT) has been proposed for the treatment of severe multiple sclerosis (MS). In a phase 2 multicenter study we selected 19 non-primary progressive MS patients showing high disease activity on the basis of both brain magnetic resonance imaging (MRI) and sustained clinical deterioration despite conventional treatments. After stem cell mobilization with cyclophosphamide (CY) and filgrastim, patients were conditioned with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), cytosine arabinoside, etoposide, and melphalan (BEAM) followed by antithymocyte globulin (ATG). Unmanipulated peripheral blood stem cells (PBSCs) were then infused. No maintenance treatment was administered with a median follow-up of 36 months (range, 12 to 72 months). All patients showed clinical stabilization or improvement; 3 subsequently deteriorated, 1 beyond the baseline. No MRI active lesions were detected after the HSCT except in 1 patient who showed a new lesion at 4.5 years. Infections were limited and restricted to 3 months after HSCT. Health-related quality of life was assessed through the 54-item MS quality of life (MSQOL-54) questionnaire, showing a statistically significant improvement in both composite scores and in most of the individual domains. HSCT is able to induce a prolonged clinical stabilization in severe progressive MS patients, resulting in both sustained treatment-free periods and quality of life improvement.
- Published
- 2005
- Full Text
- View/download PDF
27. PET scan evaluation of thymic mass after autologous peripheral blood stem-cell transplantation in an adult with non-Hodgkin's lymphoma.
- Author
-
Pagliai F, Rigacci L, Briganti V, Dini C, Castagnoli A, Vaggelli L, and Bosi A
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma complications, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Humans, Lymphoma, Non-Hodgkin complications, Male, Radiopharmaceuticals, Thymus Hyperplasia diagnostic imaging, Thymus Hyperplasia pathology, Transplantation, Autologous, Carcinoma therapy, Lymphoma, Non-Hodgkin therapy, Peripheral Blood Stem Cell Transplantation adverse effects, Thymus Hyperplasia etiology, Tomography, Emission-Computed methods
- Abstract
We report the case of a 31-year-old man with anaplastic large-cell lymphoma successfully treated with chemotherapy who showed mediastinal widening 5 months after autologous stem-cell transplantation. CT scan and PET evaluations were consistent with the diagnosis of benign thymic hyperplasia. Because of the rapid and aggressive course of this type of lymphoma, and the progressive widening of the mass at CT scan, we performed a mediastinal biopsy that confirmed these findings, showing normal thymic tissue. This is the first case of benign thymic hyperplasia defined with FDG-PET and confirmed by histologic evaluation.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.